Skip to main content

Advertisement

SpringerLink
Log in

A novel antiangiogenic approach for adjuvant therapy of pancreatic carcinoma

  • Rapid Communication
  • Published:
Langenbeck's Archives of Surgery Aims and scope Submit manuscript

Abstract

Introduction

Surgical therapy remains the only curative option for pancreatic ductal adenocarcinoma. But even after complete resection, almost all patients suffer from local tumor recurrence. Current standard adjuvant therapy with gemcitabine does not impressively affect the recurrence rate. The aim of this study was to evaluate a novel anti-angiogenic adjuvant treatment strategy by targeting the vascular endothelial growth factor receptor (VEGFR). We assayed the effects of a novel VEGFR inhibitor (ZK261991) on pancreatic carcinoma. ZK261991 is a highly selective and potent VEGFR-kinase inhibitor, which is orally available.

Methods

We used a previously established nude mouse orthotopic pancreatic cancer resection model. Subcutaneous donor tumor fragments (1 mm3) derived from human pancreatic cancer cell lines HPAF-2 and AsPC-1 were implanted in the pancreatic tail of 48 nude mice. Fourteen days afterwards, all mice underwent a histologically confirmed curative tumor resection followed by daily adjuvant oral therapy with ZK261991 (50 mg/kg; n = 24) vs. placebo (n = 24). The mice were sacrificed after 12 weeks of therapy or in case of defined endpoints. All sacrificed mice underwent autopsy. A dissemination score (local and systemic tumor spread), size of recurrent tumor mass, survival, and weight loss/gain were surveyed.

Results

Kaplan–Meier analysis of survival showed a significant benefit for mice treated with ZK261991 after HPAF-2 tumor resection: 83.8 days (95% CI 73.9–93.6) vs. 60.9 days (95% CI 48.9–73.0), p = 0.006. Adjuvant treatment with ZK261991 of AsPC-1-derived tumors showed a tendency towards a benefit compared to control but no significant difference: 75.8 days (95% CI 59.7–91.9) vs. 65.7 days (95% CI 51.6–79.7). There were no significant differences in dissemination score and size of recurrent tumor mass between the treatment groups.

Conclusion

Adjuvant anti-angiogenic therapy with the novel VEGFR-inhibitor ZK261991 resulted in a significant survival benefit after curative tumor resection in a clinically relevant orthotopic animal model of pancreatic cancer. Combination of anti-angiogenic treatment with cytotoxic agents may further improve the results of adjuvant therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer Statistics, 2010. CA Cancer J Clin 60(5):277–300. doi:10.3322/caac.20073

    Article  PubMed  Google Scholar 

  2. Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363(9414):1049–1057. doi:10.1016/S0140-6736(04)15841-8

    Article  PubMed  CAS  Google Scholar 

  3. Andersson R, Aho U, Nilsson BI, Peters GJ, Pastor-Anglada M, Rasch W, Sandvold ML (2009) Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions. Scand J Gastroenterol 44(7):782–786. doi:10.1080/00365520902745039

    Article  PubMed  CAS  Google Scholar 

  4. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D, Sarkar FH (2010) Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 8:27–33. doi:10.1038/nrgastro.2010.188, Available at: http://www.ncbi.nlm.nih.gov/pubmed/21102532 [Zugegriffen January4, 2011]

    Article  PubMed  CAS  Google Scholar 

  5. Wolff RA, Chiao P, Lenzi R, Pisters PW, Lee JE, Janjan NA, Crane CH, Evans DB, Abbruzzese JL (2000) Current approaches and future strategies for pancreatic carcinoma. Invest New Drugs 18(1):43–56

    Article  PubMed  CAS  Google Scholar 

  6. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70

    Article  PubMed  CAS  Google Scholar 

  7. Albini A, Magnani E, Noonan DM (2010) The tumor microenvironment: biology of a complex cellular and tissue society. Q J Nucl Med Mol Imaging 54(3):244–248

    PubMed  CAS  Google Scholar 

  8. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1(1):27–31

    Article  PubMed  CAS  Google Scholar 

  9. McDougall SR, Anderson ARA, Chaplain MAJ (2006) Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. J Theor Biol 241(3):564–589. doi:10.1016/j.jtbi.2005.12.022

    Article  PubMed  Google Scholar 

  10. Friesel RE, Maciag T (1995) Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 9(10):919–925

    PubMed  CAS  Google Scholar 

  11. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10(2):116–129. doi:10.1038/nrc2780

    Article  PubMed  CAS  Google Scholar 

  12. Ferrara N, Gerber H, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669–676. doi:10.1038/nm0603-669

    Article  PubMed  CAS  Google Scholar 

  13. Ahmed Z, Bicknell R (2009) Angiogenic signalling pathways. Meth Mol Biol 467:3–24

    Article  CAS  Google Scholar 

  14. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13(1):9–22

    PubMed  CAS  Google Scholar 

  15. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342. doi:10.1056/NEJMoa032691

    Article  PubMed  CAS  Google Scholar 

  16. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676. doi:10.1056/NEJMoa072113

    Article  PubMed  CAS  Google Scholar 

  17. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550. doi:10.1056/NEJMoa061884

    Article  PubMed  CAS  Google Scholar 

  18. Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Büchler MW, Korc M (1997) Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Canc Res 3(8):1309–1316

    CAS  Google Scholar 

  19. Kuehn R, Lelkes PI, Bloechle C, Niendorf A, Izbicki JR (1999) Angiogenesis, angiogenic growth factors, and cell adhesion molecules are upregulated in chronic pancreatic diseases: angiogenesis in chronic pancreatitis and in pancreatic cancer. Pancreas 18(1):96–103

    Article  PubMed  CAS  Google Scholar 

  20. Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H, Miyake M (1999) Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 79(9–10):1553–1563. doi:10.1038/sj.bjc.6690248

    Article  PubMed  CAS  Google Scholar 

  21. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K (2000) High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88(10):2239–2245

    Article  PubMed  CAS  Google Scholar 

  22. Hotz B, Backer MV, Backer JM, Buhr H, Hotz HG (2010) Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer. Neoplasia 12(10):797–806

    PubMed  CAS  Google Scholar 

  23. Hotz HG, Gill PS, Masood R, Hotz B, Buhr HJ, Foitzik T, Hines OJ, Reber HA (2002) Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer. J Gastrointest Surg 6(2):159–166, Discussion 166

    Article  PubMed  Google Scholar 

  24. Conrad C, Ischenko I, Köhl G, Wiegand U, Guba M, Yezhelyev M, Ryan AJ, Barge A, Geissler EK, Wedge SR, Jauch K, Bruns CJ (2007) Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anticancer Drugs 18(5):569–579. doi:10.1097/CAD.0b013e3280147d13

    Google Scholar 

  25. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28(22):3617–3622. doi:10.1200/JCO.2010.28.1386

    Google Scholar 

  26. Bhargava S, Stummeyer T, Hotz B, Hines OJ, Reber HA, Buhr HJ, Hotz HG (2005) Selective inhibition of endothelin receptor A as an anti-angiogenic and anti-proliferative strategy for human pancreatic cancer. J Gastrointest Surg 9(5):703–709. doi:10.1016/j.gassur.2004.11.007

    Article  PubMed  Google Scholar 

  27. Hotz HG, Hines OJ, Hotz B, Foitzik T, Buhr HJ, Reber HA (2003) Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer. J Gastrointest Surg 7(2):220–227, discussion 227–228

    Article  PubMed  Google Scholar 

  28. Thierauch K, Haberey M, Hess-Stumpp H, Huth A, Ince S, Krueger M, Bohlmann R, Zorn L, Moenning U, Meyer K, Reichel A (2007) ZK 261991. A novel VEGFR inhibitor for tumor therapy. AACR Meeting Abstracts 2007(1_Annual_Meeting):2135

  29. Hotz HG, Reber HA, Hotz B, Yu T, Foitzik T, Buhr HJ, Cortina G, Hines OJ (2003) An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas 26(4):e89–e98

    Article  PubMed  Google Scholar 

  30. Bhargava S, Hotz B, Buhr HJ, Hotz HG (2006) Etablierung eines Resektionsmodells des duktalen Pankreaskarzinoms in der Nacktmaus zur Etablierung neuer adjuvanter Therapien. In: Saeger HD, Jauch KW, Bauer H, Saeger HD, Jauch KW, Bauer H (eds) Chirurgisches Forum 2006 für experimentelle und klinische Forschung Band 35. Springer Verlag, Heidelberg, pp 141–142

    Google Scholar 

  31. Ikeda Y, Ezaki M, Hayashi I, Yasuda D, Nakayama K, Kono A (1990) Establishment and characterization of human pancreatic cancer cell lines in tissue culture and in nude mice. Jpn J Cancer Res 81(10):987–993

    PubMed  CAS  Google Scholar 

  32. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs. gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304(10):1073–1081. doi:10.1001/jama.2010.1275

    Article  PubMed  CAS  Google Scholar 

  33. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein W, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297(3):267–277. doi:10.1001/jama.297.3.267

    Article  PubMed  CAS  Google Scholar 

  34. Hotz HG, Hines OJ, Masood R, Hotz B, Foitzik T, Buhr HJ, Gill PS, Reber HA (2005) VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery 137(2):192–199. doi:10.1016/j.surg.2004.07.015

    Article  PubMed  Google Scholar 

  35. Teng L, Jin K, He K, Wang H, Cao J, Yu D (2010) Advances in combination of antiangiogenic agents targeting VEGF-binding and conventional chemotherapy and radiation for cancer treatment. J Chin Med Assoc 73(6):281–288. doi:10.1016/S1726-4901(10)70062-9

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Surgery I, Charite Medical School, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany

    Peer Joensson, Birgit Hotz, Heinz Johannes Buhr & Hubert G. Hotz

Authors
  1. Peer Joensson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Birgit Hotz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Heinz Johannes Buhr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hubert G. Hotz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peer Joensson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Joensson, P., Hotz, B., Buhr, H.J. et al. A novel antiangiogenic approach for adjuvant therapy of pancreatic carcinoma. Langenbecks Arch Surg 396, 535–541 (2011). https://doi.org/10.1007/s00423-011-0770-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00423-011-0770-2

Keywords

Search

Navigation